In this review, David C. Helfgott, MD, editorial advisory board member for Infectious Disease Advisor, focuses on infectious complications from the use of monoclonal antibodies for malignancy.
David C. Helfgott, MD
David C. Helfgott, MD, received his BA at the University of Pennsylvania and his MD at the Yale University School of Medicine. Dr Helfgott did his internship and residency at The New York Hospital and his infectious diseases fellowship at Cornell University Medical College. He is assistant attending physician at The New York-Presbyterian Hospital and assistant clinical professor of medicine at Weill Cornell Medical College. He works closely with the leukemia service there and has been involved in clinical studies of patients with infectious complications of acute leukemia.